ArticleThe Lancet. Infectious diseases2020
COVID-19: combining antiviral and anti-inflammatory treatments.
6 registry-linked trialsAbstract readComment
In one paragraph
Article in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 601 papers, 9 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
601citing papers in PubMed, 9 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study
Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial
Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact
A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia
Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial
A Multicenter, Randomized, Open-label, Controlled Trial to Assess Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia
Who cites it
601 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trials.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2022Pooled it
- Janus kinase inhibitors for the treatment of COVID-19.The Cochrane database of systematic reviews · 2022Pooled it
- Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection.Inflammopharmacology · 2022Pooled it
- JAK inhibitors and COVID-19.Journal for immunotherapy of cancer · 2022Pooled it
- Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- Pooled it
- Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.Frontiers in medicine · 2022Pooled it
- Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study.Molecular psychiatry · 2021Pooled it
- Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.Critical care (London, England) · 2023Trial
- Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2022Trial
- Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.The Lancet. Respiratory medicine · 2021Trial
- Machine Learning and Molecular Modeling for Drug Repurposing Targeting Potential PI3Kα Inhibitors in Post-CoViD-19 Pulmonary Fibrosis.ACS omega · 2026Article
- RAAS antagonists dampen the SARS-CoV-2 infection in ex-vivo cultured human precision-cut lung slices.Respiratory research · 2026Article
- Machine learning for drug-target interaction prediction: A comprehensive review of models, challenges, and computational strategies.Computational and structural biotechnology journal · 2026Review
- Targeting PTP4A3 with KVX-053 mitigates alcohol-amplified SARS-CoV-2 spike protein-induced acute lung injury.Frontiers in pharmacology · 2026Article
- Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation.Frontiers in cellular and infection microbiology · 2026Review
- Network-Medicine-Guided Drug Repurposing for Alzheimer's Disease: A Multi-Dimensional Systems Pharmacology Approach.International journal of molecular sciences · 2025Article
- Artificial Intelligence in Small-Molecule Drug Discovery: A Critical Review of Methods, Applications, and Real-World Outcomes.Pharmaceuticals (Basel, Switzerland) · 2025Review
541 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
7 authors.
Justin StebbingDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK. Electronic address: j.stebbing@imperial.ac.uk.
Anne PhelanBenevolent AI, London, UK.
Ivan GriffinBenevolent AI, London, UK.
Catherine TuckerBenevolent AI, London, UK.
Olly OechsleBenevolent AI, London, UK.
Dan SmithBenevolent AI, London, UK.
Peter RichardsonBenevolent AI, London, UK.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antiviral AgentsAnti-Inflammatory AgentsAzetidinesBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentPandemicsPneumonia, ViralPurinesPyrazolesSARS-CoV-2SulfonamidesAnti-Inflammatory AgentsAntiviral AgentsAzetidinesbaricitinibPurinesPyrazolesSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04320277ClinicalTrials.gov
NCT04345289ClinicalTrials.gov
NCT04358614ClinicalTrials.gov
NCT04399798ClinicalTrials.gov
NCT04517162ClinicalTrials.gov
NCT04627519ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.